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c o r r e s p o n d e n c e
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Trial of the Route of Early Nutritional Support in Critically  
Ill Adults
To the Editor: In reporting the results of the 
CALORIES trial, Harvey and colleagues (Oct. 30 
issue)1 indicate that the route of delivery of early 
nutritional support in the intensive care unit 
(ICU) does not alter patient outcomes. This mes-
sage contradicts the widely held belief that the 
enteral route, which is more physiological, is to 
be preferred. However, we think that there is an-
other implicit message: this study suggests that 
the role of nutritional support in the ICU should 
be reconsidered. Past evidence has led researchers 
to implement an overzealous approach to nutri-
tional support in patients in the ICU. Given the 
results from the present study, we should proba-
bly take a step backward. There is still an unan-
swered question regarding which critically ill 
patients should receive early nutritional support. 
Some recent trials1-3 suggest that such patients 
may be those with depleted body stores due to 
malnutrition rather than all those who are at nu-
tritional risk as a consequence of critical illness. 
We believe that targeting early nutritional support 
to the right patients constitutes a key point that 
should be addressed.
Once that question is addressed, we could 
focus again on timing, the route of delivery, 
protein and caloric targets, and nutrients that 
have putative pharmacologic activity.
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To the Editor: The external validity of the 
study by Harvey et al. is questionable in our 
view. The inclusion criteria do not adhere to 
standards of care1,2 based on updated literature 
(see www.criticalcarenutrition.com). These stan-
dards call for the preferential use of enteral nu-
trition in patients who are able to receive it. The 
area in which experts and guidelines disagree is 
the timing of supplemental parenteral nutrition 
in patients who are unable to receive sufficient en-
teral nutrition without unacceptable side effects.3,4 
The lack of advantage of early parenteral nutri-
tion in the CALORIES study is not surprising, 
given that some patients may not have needed any 
nutritional support and the most appropriate route 
was not assessed in other patients in this trial. 
Both the low protein intake and the low caloric 
intake, as well as the low number of patients per 
center, are other major concerns. In our view, the 
primary outcome, all-cause mortality at 30 days, 
was also unlikely to be related to the efficacy of 
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the therapeutic interventions. The contribution 
of this study would have been much more valu-
able after a selection of patients in whom the 
adequacy of nutrition mattered and could be 
properly evaluated.
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To the Editor: In my view, the CALORIES trial 
fails to support the hypothesis that the paren-
teral route is superior to the enteral route for the 
delivery of early nutritional support in adults. Ac-
cording to the trial design, even patients who 
were assigned to the parenteral group received 
the benefits of enteral nutrition. A significant 
number of patients in the parenteral group re-
ceived enteral nutrition both during the 120-hour 
period and after it. Among 700 patients in the 
parenteral group, only 13 patients (1.9%) exclu-
sively received parenteral nutrition after the in-
tervention. Extrapolation of such a short dura-
tion of parenteral nutrition with or without 
enteral nutritional support to estimate the effect 
on mortality at 30 days is not ideal. Data about 
coexisting diseases such as diabetes mellitus, 
hypertension, congestive heart failure, and chronic 
obstructive pulmonary disease — all of which 
may have an important effect on secondary out-
come measures — are not mentioned. The sum-
mary of the original protocol (available with the 
full text of the article at NEJM.org) mentions a 
primary objective to estimate the incremental 
cost-effectiveness of early parenteral nutrition 
as compared with early enteral nutrition at 1 year. 
I do not find mention of this in the article.
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The Authors Reply: CALORIES was a pragmatic 
trial evaluating the effectiveness of the paren-
teral route as compared with the enteral route for 
early nutritional support in critically ill adults. 
Nutritional support was initiated within 36 hours 
after unplanned admission to one of a represen-
tative sample of ICUs in England and was used 
exclusively for 120 hours.
The suggestion by Cereda and Caccialanza that 
critically ill patients should receive early nutri-
tional support only if they are malnourished is 
interesting but not directly relevant to our trial. 
Therefore, we do not believe that our data can be 
interpreted either to support or to refute their 
hypothesis, which we agree merits further con-
sideration.
Preiser and colleagues appear to advocate 
opinion-based guidelines and a meta-analysis of 
small, older, and methodologically compromised 
studies, rather than evidence from a large, rigor-
ous, randomized, controlled trial. We disagree 
with such an approach. Contrary to their asser-
tion, all patients recruited into the CALORIES 
trial met standard criteria to receive nutritional 
support, as our article made clear. Moreover, ef-
fectiveness, not efficacy, was tested in our prag-
matic trial. Despite their belief that mortality 
was unlikely to be affected by the route of nutri-
tional support, the meta-analysis by Simpson and 
Doig1 suggested otherwise. The energy intake 
and protein intake in our pragmatic trial were 
similar to or greater than those in other studies 
of nutritional support in clinical practice.2 In 
addition, the number of eligible patients recruit-
ed per center was greater than that in another 
recent, large, multicenter trial of nutritional sup-
port in intensive care.3
Ramamurthy’s statement that benefits are as-
sociated with the use of the enteral route rather 
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than the parenteral route is not supported by our 
trial. Our aim was to evaluate the effect of the 
route for the delivery of early nutritional sup-
port, and the number of patients in the paren-
teral group who were fed enterally during the 
120-hour intervention period was small. Base-
line characteristics, including coexisting condi-
tions, were well balanced between the groups 
and were summarized in Table 1 of our article. 
A 1-year follow-up study is under way to assess 
longer-term outcomes and to provide an inte-
grated economic evaluation.
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Etanercept Tapering in Rheumatoid Arthritis
To the Editor: The study by Emery et al. (Nov. 6 
issue)1 contravenes the recommendations not to 
use biologic agents as first-line treatment for 
rheumatoid arthritis. Furthermore, the study uses 
biased control groups (methotrexate monotherapy 
and placebo) and does not compare the combina-
tion treatment (etanercept plus methotrexate) 
with a balanced combination of disease-modify-
ing antirheumatic drugs (DMARDs). Several 
studies have shown that such a combination is as 
effective as biologic treatment, especially when 
combined with a short-term initial course of glu-
cocorticoids.2-4
Owing to a lack of comparison with DMARD 
combination therapy, the conclusion of the study 
is inappropriately biased in favor of etanercept. 
The correct first-line treatment algorithm for 
rheumatoid arthritis includes DMARD mono-
therapy and combination therapy. Biologic agents 
should be reserved as second-line therapy for 
patients with rheumatoid arthritis who have an 
insufficient response to combination DMARD 
treatment.
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The Authors Reply: Graudal and Jürgens con-
tend that our study contravenes recommendations 
not to use biologic agents as first-line therapy for 
rheumatoid arthritis. The recommendations of the 
European League against Rheumatism (EULAR) 
in 2010,1 when the study started, stated that bio-
logic agents could be used first in the case of 
severe disease. In 2013, the recommendations2 
were modified (not by unanimous decision) to 
suggest that conventional synthetic DMARDs be 
used first. Graudal and Jürgens also indicate that 
a comparison with methotrexate monotherapy 
rather than with combination DMARDs biased 
the study. However, the 2013 EULAR recommen-
dations do not endorse initial triple therapy but 
suggest initial methotrexate monotherapy, albeit 
plus glucocorticoids.
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